The Safety of Recombinant Factor VIIa in Cardiac Surgery
نویسندگان
چکیده
منابع مشابه
Bleeding after cardiac surgery - The role of recombinant factor VIIa
Cardiac surgery carries the risk of significant blood loss requiring the transfusion of blood products. In addition to such blood loss, international studies have shown that severe bleeding necessitating re-operation occurs in 3–5% of patients. Morbidity and mortality are significantly increased, so effective and safe haemostatic measures will decisively improve outcome of patients. Recombinant...
متن کامل[Bleeding after cardiac surgery: the role of recombinant factor VIIa].
Cardiac surgery carries a remarkable risk of blood loss requiring transfusion of blood products. Moreover, severe bleeding necessitating reoperation occurs in 3-5% of patients according to international studies. These patients face a significantly higher morbidity and mortality. This underscores the need for a safe and effective haemostatic therapy, which may significantly improve the outcome. ...
متن کاملUse of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery.
Significant post-operative bleeding can be encountered in a small population of pediatric surgical patients requiring cardiopulmonary bypass (CPB). Recombinant factor VIIa (NovoSeven) has been advocated as a possible off-label rescue therapy for these individuals when conventional blood component therapy alone is inadequate. This study retrospectively evaluates rFVIIa administration for the tre...
متن کاملRecombinant factor VIIa: safety and efficacy.
PURPOSE OF REVIEW Recombinant factor VIIa has been increasingly used to provide hemostasis in nonapproved indications. This trend has resulted in concerns about safety, efficacy and costs. RECENT FINDINGS Recombinant factor VIIa seems to have hemostatic effects in posttrauma and perisurgery excessive bleeding, although further studies are required. Recombinant factor VIIa may be used to rever...
متن کاملTreatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
CARDIAC surgery with cardiopulmonary bypass (CPB) poses serious hemostatic challenges in Jehovah’s Witnesses, who refuse blood transfusions on religious grounds. Excessive bleeding ( 2 l) after cardiac surgery is encountered in 5–7% of Jehovah’s Witness patients, and necessitates reexploration in 3.6% of cases. Recombinant factor VIIa (rFVIIa, NovoSeven®; Novo Nordisk, Princeton, NJ), produced ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Anaesthesia and Intensive Care
سال: 2010
ISSN: 0310-057X,1448-0271
DOI: 10.1177/0310057x1003800409